Ich stimme der Verwendung von Cookies zu. Auch wenn ich diese Website weiter nutze, gilt dies als Zustimmung.

Bitte lesen und akzeptieren Sie die Datenschutzinformation und Cookie-Informationen, damit Sie unser Angebot weiter nutzen können. Natürlich können Sie diese Einwilligung jederzeit widerrufen.






21st Austria weekly - Valneva, Palfinger (25/01/2021)

31.01.2021

Palfinger: Palfinger, a leading international manufacturer of innovative lifting solutions, is currently the target of an ongoing global cyber attack. IT infrastructure is disrupted at the moment (including sending and receiving emails, ERP systems). A large proportion of the group's worldwide locations are affected. It is not possible to estimate the precise extent and duration of the attack or its consequences at this time. "Work is being carried out intensively on a solution", the company stated.
Palfinger: weekly performance: -5.02%

Valneva: Valneva, an Austrian/French specialty vaccine company, and Instituto Butantan, producer of immunobiologic products, today announced the signing of definitive agreements for the development, manufacturing and marketing of Valneva’s single-shot chikungunya vaccine, VLA1553, in Low and Middle Income Countries (LMICs). This finalization follows the signing of a binding term sheet in May 2020.  The collaboration falls within the framework of the USD 23.4 mn funding agreement Valneva signed with the Coalition for Epidemic Preparedness Innovations (CEPI) in July 2019. Under the collaboration, Valneva will transfer its chikungunya vaccine technology to Instituto Butantan, who will develop, manufacture and commercialize the vaccine in LMICs. In addition, Instituto Butantan will provide certain clinical and Phase 4 observational studies that Valneva will use to meet regulatory requirements. The agreement includes small upfront and technology transfer milestones. Thomas Lingelbach, Chief Executive Officer of Valneva, commented, “The dreadful impact of the COVID-19 pandemic on the world has underlined the importance of vaccines to combat public health crises. Chikungunya outbreaks have impacted over 120 countries and affected millions, yet no vaccine or treatment is currently available to prevent this debilitating disease. We look forward to working with Instituto Butantan to help address this urgent public health need and speed up the development of a chikungunya vaccine in LMICs, which are high outbreak risk areas.”
Valneva: weekly performance: 4.41%

(From the 21st Austria weekly https://www.boerse-social.com/21staustria (25/01/2021)


Partners









latest 21st Austria

21st Austria weekly - Valneva, Palfinger (25/01/2021)


31.01.2021, 2200 Zeichen



Palfinger: Palfinger, a leading international manufacturer of innovative lifting solutions, is currently the target of an ongoing global cyber attack. IT infrastructure is disrupted at the moment (including sending and receiving emails, ERP systems). A large proportion of the group's worldwide locations are affected. It is not possible to estimate the precise extent and duration of the attack or its consequences at this time. "Work is being carried out intensively on a solution", the company stated.
Palfinger: weekly performance: -5.02%

Valneva: Valneva, an Austrian/French specialty vaccine company, and Instituto Butantan, producer of immunobiologic products, today announced the signing of definitive agreements for the development, manufacturing and marketing of Valneva’s single-shot chikungunya vaccine, VLA1553, in Low and Middle Income Countries (LMICs). This finalization follows the signing of a binding term sheet in May 2020.  The collaboration falls within the framework of the USD 23.4 mn funding agreement Valneva signed with the Coalition for Epidemic Preparedness Innovations (CEPI) in July 2019. Under the collaboration, Valneva will transfer its chikungunya vaccine technology to Instituto Butantan, who will develop, manufacture and commercialize the vaccine in LMICs. In addition, Instituto Butantan will provide certain clinical and Phase 4 observational studies that Valneva will use to meet regulatory requirements. The agreement includes small upfront and technology transfer milestones. Thomas Lingelbach, Chief Executive Officer of Valneva, commented, “The dreadful impact of the COVID-19 pandemic on the world has underlined the importance of vaccines to combat public health crises. Chikungunya outbreaks have impacted over 120 countries and affected millions, yet no vaccine or treatment is currently available to prevent this debilitating disease. We look forward to working with Instituto Butantan to help address this urgent public health need and speed up the development of a chikungunya vaccine in LMICs, which are high outbreak risk areas.”
Valneva: weekly performance: 4.41%

(From the 21st Austria weekly https://www.boerse-social.com/21staustria (25/01/2021)



BSN Podcasts
Christian Drastil: Wiener Börse Plausch

Börsepeople im Podcast S12/08: Robert Abend




 

Bildnachweis

Aktien auf dem Radar:Amag, Palfinger, SBO, Addiko Bank, Flughafen Wien, Austriacard Holdings AG, EVN, EuroTeleSites AG, Pierer Mobility, Semperit, Bawag, Kostad, Wolford, Oberbank AG Stamm, Polytec Group, ams-Osram, Agrana, CA Immo, Erste Group, Immofinanz, Kapsch TrafficCom, Mayr-Melnhof, OMV, Österreichische Post, Strabag, Telekom Austria, Uniqa, VIG, Wienerberger, Covestro, Sartorius.


Random Partner

Marinomed
Erforscht und entwickelt völlig neuartige Technologieplattformen, die innovative Therapien gegen Atemwegs- und Augenerkrankungen ermöglichen. Aus wissenschaftlichen Ideen werden so neue Patente, Marken und Produkte geschaffen.

>> Besuchen Sie 68 weitere Partner auf boerse-social.com/partner


Useletter

Die Useletter "Morning Xpresso" und "Evening Xtrakt" heben sich deutlich von den gängigen Newslettern ab. Beispiele ansehen bzw. kostenfrei anmelden. Wichtige Börse-Infos garantiert.

Newsletter abonnieren

Runplugged

Infos über neue Financial Literacy Audio Files für die Runplugged App
(kostenfrei downloaden über http://runplugged.com/spreadit)

per Newsletter erhalten